Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jurij Furst"'
Autor:
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, Francis Arickx, Alexander Bybau, Tomasz Bochenek, Marc Van De Casteele, Eduardo Diogene, Jurij Furst, Kristina Garuoliene, Martin van der Graaff, Jolanta Gulbinovic, Alan Haycox, Jan Jones, Roberta Joppi, Ott Laius, Irene Langner, Anthony Martin, Vanda Markovic-Pekovic, Laura McCullagh, Einar Magnusson, Ellen Nilsen, Gisbert Selke, Catherine Sermet, Steven Simoens, Robert Sauermann, Ad Schuurman, Ricardo Ramos, Vera Vlahovic-Palcevski, Corinne Zara, Brian Godman
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further
Externí odkaz:
https://doaj.org/article/40d4ad711a0845b293f34d8201689534
Autor:
Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell, Johanna C. Meyer
Publikováno v:
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Introduction: There are positive aspects regarding the prescribing of fixed-dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5b26d8bdc871fe68dba57522fc9121
https://strathprints.strath.ac.uk/71606/13/Godman_etal_ERPOR_2020_Fixed_dose_drug_combinations_are_they_pharmacoeconomically.pdf
https://strathprints.strath.ac.uk/71606/13/Godman_etal_ERPOR_2020_Fixed_dose_drug_combinations_are_they_pharmacoeconomically.pdf
Autor:
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A. Vreman, Cecilia Tollin, Johan Pontén, Dalia Dawoud, Jamie Elvidge, Nick Crabb, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke Pisters-van Roy, Áron Vincziczki, Emad Almomani, Maja Vajagic, Z. Gulsen Oner, Mirna Matni, Jurij Fürst, Rabia Kahveci, Wim G. Goettsch, Zoltán Kaló
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower i
Externí odkaz:
https://doaj.org/article/cad946d469d047ba9bcf6c3dcb92c059
Autor:
Alice Pisana, Björn Wettermark, Amanj Kurdi, Biljana Tubic, Caridad Pontes, Corinne Zara, Eric Van Ganse, Guenka Petrova, Ileana Mardare, Jurij Fürst, Marta Roig-Izquierdo, Oyvind Melien, Patricia Vella Bonanno, Rita Banzi, Vanda Marković-Peković, Zornitsa Mitkova, Brian Godman
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluati
Externí odkaz:
https://doaj.org/article/a7cb1f6351164908896e1d25ae912be5
Publikováno v:
Zdravniški Vestnik, Vol 89, Iss 7-8, Pp 408-422 (2020)
Izhodišče: Kazalniki predpisovanja zdravil so izbrani podatki, ki delno osvetljujejo zdravnikovo delo na področju predpisovanja zdravil. Zavod za zdravstveno zavarovanje Slovenije (ZZZS) je v sodelovanju s predstavniki pediatrične stroke pripravi
Externí odkaz:
https://doaj.org/article/6f5e7ecfffaf4882a6f484b9efce66f2
Autor:
Ajda Bedene, Anita Strmljan, Eveline L. A. van Dorp, Mitja Udovič, Willem M. Lijfering, Marieke Niesters, Frits R. Rosendaal, Albert Dahan, Jurij Fürst
Publikováno v:
Frontiers in Pain Research, Vol 2 (2021)
Background: Prescribing practice of pain medication is changing in the Netherlands; opioids are used more often instead of nonsteroidal anti-inflammatory drugs (NSAIDs), therefore we aimed to compare the use of pain medication with Slovenia which has
Externí odkaz:
https://doaj.org/article/7113f18cf55644e8ace3702f45118d66
Autor:
Brian Godman, Mainul Haque, Trudy Leong, Eleonora Allocati, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Carlos Vassalo, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M. Muksudul Alam, Iffat Jahan, Zubair Mahmood Kamal, Humaira Hasin, Munzur-E-Murshid, Shamsun Nahar, Monami Haque, Siddhartha Dutta, Jha Pallavi Abhayanand, Rimple Jeet Kaur, Godfrey Mutashambara Rwegerera, Renata Cristina Rezende Macedo do Nascimento, Isabella Piassi Dias Godói, Mohammed Irfan, Adefolarin A. Amu, Patrick Matowa, Joseph Acolatse, Robert Incoom, Israel Abebrese Sefah, Jitendra Acharya, Sylvia Opanga, Lisper Wangeci Njeri, David Kimonge, Hye-Young Kwon, SeungJin Bae, Karen Koh Pek Khuan, Abdullahi Rabiu Abubakar, Ibrahim Haruna Sani, Tanveer Ahmed Khan, Shahzad Hussain, Zikria Saleem, Oliver Ombeva Malande, Thereza Piloya-Were, Rosana Gambogi, Carla Hernandez Ortiz, Luke Alutuli, Aubrey Chichonyi Kalungia, Iris Hoxha, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Ott Laius, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuoliene, Jolanta Gulbinovič, Magdalene Wladysiuk, Jakub Rutkowski, Ileana Mardare, Jurij Fürst, Stuart McTaggart, Sean MacBride-Stewart, Caridad Pontes, Corinne Zara, Eunice Twumwaa Tagoe, Rita Banzi, Janney Wale, Mihajlo Jakovljevic
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control inclu
Externí odkaz:
https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad
Autor:
Márta Szegedi, Tamás Zelei, Francis Arickx, Anna Bucsics, Emanuelle Cohn-Zanchetta, Jurij Fürst, Maria Kamusheva, Pawel Kawalec, Guenka Petrova, Juraj Slaby, Ewa Stawowczyk, Milan Vocelka, Ingrid Zechmeister-Koss, Zoltán Kaló, Mária Judit Molnár
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-8 (2018)
Abstract Background Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU). Objectives To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients,
Externí odkaz:
https://doaj.org/article/a2f788acf7c7464e84e7030297f9dcfe
Autor:
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett, Arnold G. Vulto
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of thi
Externí odkaz:
https://doaj.org/article/91efa0738a404ac58954a5cf23bc3c10
Autor:
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso Guerra, Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell, Alan Haycox
Publikováno v:
Frontiers in Public Health, Vol 6 (2018)
Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices alon
Externí odkaz:
https://doaj.org/article/44e09c6a8ab54400ba7f5f970ab42861